Description
Indications
- Corynebacterium pseudodiphtheriticum
- Corynebacterium striatum
- Haemophilus influenzae
- Moraxella lacunata
- Staphylococcus aureus
- Staphylococcus epidermidis
- Staphylococcus hominis
- Staphylococcus lugdunensis
- Streptococcus mitis group
- Streptococcus oralis
- Streptococcus pneumoniae
- Streptococcus salivarius
Efficacy for this organism was studied in fewer than 10 infections.
Pharmacology
Plasma concentrations of Besifloxacin were measured in adult patients with suspected bacterial conjunctivitis who received Besifloxacin bilaterally three times a day (16 doses total). Following the first and last dose, the maximum plasma Besifloxacin concentration in each patient was less than 1.3 ng/ml. The mean Besifloxacin C max was 0.37 ng/ml on day 1 and 0.43 ng/ml on day 6. The average elimination half-life of Besifloxacin in plasma following multiple dosing was estimated to be 7 hours.
Dosage & Administration
Pediatric Use: The safety and effectiveness of Besifloxacin in infants below one year of age have not been established. The efficacy of Besifloxacin in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials.
Geriatric Use: No overall differences in safety and effectiveness have been observed between elderly and younger patients.





Reviews
There are no reviews yet.